{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Progression-Free+Survival", "query": { "condition": "Progression-Free Survival" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 70, "total_pages": 7, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Progression-Free+Survival&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-07-23T03:21:39.895Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00642603", "title": "A Study of Xeloda (Capecitabine) in Combination With Avastin + Short Course Chemotherapy in Patients With Metastatic Colorectal Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Colorectal Cancer" ], "interventions": [ { "name": "capecitabine [Xeloda]", "type": "DRUG" }, { "name": "bevacizumab [Avastin]", "type": "DRUG" }, { "name": "oxaliplatin", "type": "DRUG" }, { "name": "irinotecan", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hoffmann-La Roche", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 41, "start_date": "2008-05", "completion_date": "2009-03", "has_results": true, "last_update_posted_date": "2018-03-29", "last_synced_at": "2026-07-23T03:21:39.895Z", "location_count": 76, "location_summary": "PARK Springs, Arizona • Sedona, Arizona • Tucson, Arizona + 68 more", "locations": [ { "city": "PARK Springs", "state": "Arizona" }, { "city": "Sedona", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Anaheim", "state": "California" }, { "city": "Colton", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00642603" }, { "nct_id": "NCT00463060", "title": "Sutent and Radiation as Treatment for Limited Extent Metastatic Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Cancer" ], "interventions": [ { "name": "sunitinib malate (Sutent)", "type": "DRUG" }, { "name": "radiotherapy", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "PROCEDURE" ], "sponsor": "Icahn School of Medicine at Mount Sinai", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 47, "start_date": "2007-01", "completion_date": "2014-07", "has_results": true, "last_update_posted_date": "2018-07-18", "last_synced_at": "2026-07-23T03:21:39.895Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT00463060" }, { "nct_id": "NCT06943872", "title": "A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Chronic Lymphocytic Leukemia", "Small Lymphocytic Lymphoma" ], "interventions": [ { "name": "Sonrotoclax", "type": "DRUG" }, { "name": "Obinutuzumab", "type": "DRUG" }, { "name": "Rituximab", "type": "DRUG" }, { "name": "Venetoclax", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "BeOne Medicines", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 630, "start_date": "2025-06-11", "completion_date": "2031-12", "has_results": false, "last_update_posted_date": "2026-07-08", "last_synced_at": "2026-07-23T03:21:39.895Z", "location_count": 35, "location_summary": "Laguna Hills, California • Orange, California • Palo Alto, California + 31 more", "locations": [ { "city": "Laguna Hills", "state": "California" }, { "city": "Orange", "state": "California" }, { "city": "Palo Alto", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "Aurora", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT06943872" }, { "nct_id": "NCT02392078", "title": "Laser Ablation of Abnormal Neurological Tissue Using Robotic NeuroBlate System", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Metastatic Brain Tumor", "Primary Brain Tumor", "Epileptic/Seizure Foci", "Movement Disorders" ], "interventions": [ { "name": "NeuroBlate System", "type": "DEVICE" } ], "intervention_types": [ "DEVICE" ], "sponsor": "Monteris Medical", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 1153, "start_date": "2015-10", "completion_date": "2023-09-30", "has_results": true, "last_update_posted_date": "2025-04-24", "last_synced_at": "2026-07-23T03:21:39.895Z", "location_count": 26, "location_summary": "Phoenix, Arizona • Little Rock, Arkansas • La Jolla, California + 20 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "La Jolla", "state": "California" }, { "city": "Orange", "state": "California" }, { "city": "New Haven", "state": "Connecticut" } ], "official_url": "https://clinicaltrials.gov/study/NCT02392078" }, { "nct_id": "NCT07029776", "title": "MMulti-Immune HR; Multi-Target Immunotherapy for High-Risk Multiple Myeloma", "overall_status": "NOT_YET_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Multiple Myeloma (MM)" ], "interventions": [ { "name": "teclistamab+daratumumab followed by talquetamab+daratumumab followed by duration treatment with daratumumab and lenalidomide extended/maintenance", "type": "DRUG" }, { "name": "melphalan (MEL)-based hematopietic stem cell transplantation (HSCT) followed by drug therapy", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "PROCEDURE" ], "sponsor": "University of Arkansas", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 50, "start_date": "2026-07-01", "completion_date": "2032-04-01", "has_results": false, "last_update_posted_date": "2026-03-03", "last_synced_at": "2026-07-23T03:21:39.895Z", "location_count": 1, "location_summary": "Little Rock, Arkansas", "locations": [ { "city": "Little Rock", "state": "Arkansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT07029776" }, { "nct_id": "NCT04028479", "title": "The Registry of Oncology Outcomes Associated With Testing and Treatment", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Adenocarcinoma", "Adenocystic Carcinoma", "Anal Cancer", "Appendix Cancer", "Brain Tumor", "Glioblastoma", "Astrocytoma", "Bile Duct Cancer", "Cholangiocarcinoma", "Bladder Cancer", "Bone Cancer", "Synovial Sarcoma", "Chondrosarcoma", "Liposarcoma", "Sarcoma, Kaposi", "Sarcoma,Soft Tissue", "Sarcoma", "Osteosarcoma", "CNS Cancer", "Brain Stem Neoplasms", "Breast Cancer", "Cervical Cancer", "Colorectal Cancer", "Rectal Cancer", "Colon Cancer", "Esophageal Cancer", "Esophagus Cancer", "Cancer of Colon", "Pancreatic Cancer", "Cancer of Pancreas", "Testis Cancer", "Testicular Cancer", "Ureter Cancer", "Renal Cell Carcinoma", "Kidney Cancer", "Gestational Trophoblastic Tumor", "Head and Neck Neoplasms", "Parotid Tumor", "Larynx Cancer", "Tongue Cancer", "Pharynx Cancer", "Salivary Gland Cancer", "Acute Myeloid Leukemia", "Chronic Myeloid Leukemia", "Acute Lymphoblastic Leukemia", "Multiple Myeloma", "Non Hodgkin Lymphoma", "Carcinoid Tumor", "Lung Cancer", "Neuroendocrine Tumors", "Mesothelioma", "Thyroid Cancer", "Parathyroid Neoplasms", "Adrenal Cancer", "Small Bowel Cancer", "Stomach Cancer", "Liver Cancer", "Hepatic Cancer", "Melanoma", "Skin Cancer", "Unknown Primary Tumors", "Uterine Cancer", "Fallopian Tube Cancer", "Ovarian Cancer", "Prostate Cancer", "Vaginal Cancer", "Penile Cancer", "Vulvar Cancer", "Waldenstrom Macroglobulinemia", "Cancer, Advanced", "Thymus Cancer", "Nasopharyngeal Carcinoma", "Multiple Endocrine Neoplasia", "Pheochromocytoma", "Small Cell Carcinoma", "Pulmonary Carcinoma" ], "interventions": [ { "name": "Biomarker Testing (L)", "type": "DIAGNOSTIC_TEST" }, { "name": "Systemic Treatment (T)", "type": "DRUG" }, { "name": "Patient Reported Outcomes (P)", "type": "OTHER" } ], "intervention_types": [ "DIAGNOSTIC_TEST", "DRUG", "OTHER" ], "sponsor": "Taproot Health", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 167, "start_date": "2021-05-05", "completion_date": "2024-10-31", "has_results": false, "last_update_posted_date": "2024-12-18", "last_synced_at": "2026-07-23T03:21:39.895Z", "location_count": 2, "location_summary": "Idaho Falls, Idaho • Laredo, Texas", "locations": [ { "city": "Idaho Falls", "state": "Idaho" }, { "city": "Laredo", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT04028479" }, { "nct_id": "NCT01681368", "title": "Birinapant for Advanced Ovarian, Fallopian Tube, and Peritoneal Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Epithelial Ovarian Cancer", "Peritoneal Neoplasms", "Fallopian Tube Neoplasms" ], "interventions": [ { "name": "Birinapant (TL32711)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 11, "start_date": "2012-08-15", "completion_date": "2014-04-30", "has_results": true, "last_update_posted_date": "2017-05-30", "last_synced_at": "2026-07-23T03:21:39.895Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT01681368" }, { "nct_id": "NCT04689828", "title": "177Lu-PSMA-617 vs. Androgen Receptor-Directed Therapy in the Treatment of Progressive Metastatic Castrate Resistant Prostate Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Prostatic Neoplasms" ], "interventions": [ { "name": "177Lu-PSMA-617", "type": "DRUG" }, { "name": "68Ga-PSMA-11", "type": "DRUG" }, { "name": "ARDT", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "100 Years", "sex": "MALE", "summary": "18 Years to 100 Years · Male only" }, "enrollment_count": 469, "start_date": "2021-06-15", "completion_date": "2026-09-30", "has_results": true, "last_update_posted_date": "2026-07-08", "last_synced_at": "2026-07-23T03:21:39.895Z", "location_count": 20, "location_summary": "Denver, Colorado • Gainesville, Florida • New Orleans, Louisiana + 13 more", "locations": [ { "city": "Denver", "state": "Colorado" }, { "city": "Gainesville", "state": "Florida" }, { "city": "New Orleans", "state": "Louisiana" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT04689828" }, { "nct_id": "NCT03546894", "title": "A Study to Determine Progression-free Survival (PFS) and Evaluate Participant Experience for Participants With Metastatic Anaplastic Lymphoma Kinase-positive (ALK+) Non-Small Cell Lung Cancer (NSCLC) Treated With Anaplastic Lymphoma Kinase (ALK) Inhibitors", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Anaplastic Lymphoma Kinase-positive", "Carcinoma Non-small-cell Lung" ], "interventions": [ { "name": "Brigatinib", "type": "DRUG" }, { "name": "Alectinib", "type": "DRUG" }, { "name": "Ceritinib", "type": "DRUG" }, { "name": "Lorlatinib", "type": "DRUG" }, { "name": "Any FDA Approved ALK Inhibitors", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Takeda", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 111, "start_date": "2018-07-23", "completion_date": "2023-02-13", "has_results": false, "last_update_posted_date": "2024-07-15", "last_synced_at": "2026-07-23T03:21:39.895Z", "location_count": 1, "location_summary": "Maynard, Massachusetts", "locations": [ { "city": "Maynard", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT03546894" }, { "nct_id": "NCT05155254", "title": "IO102-IO103 in Combination With Pembrolizumab Versus Pembrolizumab Alone in Advanced Melanoma (IOB-013 / KN-D18)", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Metastatic Melanoma", "Unresectable Melanoma" ], "interventions": [ { "name": "IO102-IO103", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "IO Biotech", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 407, "start_date": "2022-05-17", "completion_date": "2027-09", "has_results": false, "last_update_posted_date": "2025-08-28", "last_synced_at": "2026-07-23T03:21:39.895Z", "location_count": 4, "location_summary": "Orange City, Florida • Orlando, Florida • Buffalo, New York + 1 more", "locations": [ { "city": "Orange City", "state": "Florida" }, { "city": "Orlando", "state": "Florida" }, { "city": "Buffalo", "state": "New York" }, { "city": "Richmond", "state": "Virginia" } ], "official_url": "https://clinicaltrials.gov/study/NCT05155254" } ] }